Speech Date

2024/12/20

Theme

Announcement of the change of Financial Officer, Accounting Officer and Acting Spokesperson

Fact Date

2024-12-20

Describe

1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):
Financial Officer, Accounting Officer and Acting Spokesperson
2.Date of occurrence of the change:2024/12/20
3.Name, title, and resume of the previous position holder:
(1) Financial Officer: Lin, Li-Fen / Accounting Officer
(2) Accounting Officer: Lin, Li-Fen / Accounting Officer
(3) Acting Spokesperson: Lin, Li-Fen / Accounting Officer
4.Name, title, and resume of the new position holder:
(1) Financial Officer: Gao, Heng-Zheng / Accounting Manager (acting)
(2) Accounting Officer: Gao, Heng-Zheng / Accounting Manager (acting)
(3) Acting Spokesperson: Ma, Fang / Internal Audit Officer (acting)
5.Type of change (please enter: ”resignation”,
”position adjustment”, ”dismissal”, ”retirement”,
”death” or ”new replacement”):Resignation
6.Reason for the change:Personal career planning
7.Effective date:2024/12/20
8.Any other matters that need to be specified:
The positions of Financial Officer, Accounting Officer and Acting
Spokesperson are all temporary. The official appointees will be announced
after the formal appointment by the Board of Directors.

Speech Date

2024/11/19

Theme

Announcement the company is invited to attend the online institutional investor conference held by Horizon Securities

Fact Date

2024-12-03

Describe

1.Date of institutional investor conference:2024/12/03
2.Time of institutional investor conference:14:30
3.Location of institutional investor conference:
Online institutional investor conference
4.Outline of institutional investor conference:
The company is invited to attend the online institutional investor
conference held by Horizon Securities to explain the business performance.
Contact person: Ms. Kuo / Ms. Liu of Horizon Securities
Contact number: 02-2700-8899#8313/#8337
Email: jessica.kuo@honsec.com.tw / mary.liu@honsec.com.tw
5.Any other matters that need to be specified:None

Speech Date

2024/11/11

Theme

Announcement of the Board of Directors approved the consolidated financial statements for the third quarter of 2024

Fact Date

2024-11-11

Describe

1.Date of the board of directors submitted or approved:2024/11/11
2.Date of the audit committee approved:2024/11/11
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2024/01/01~2024/09/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):3,168,349
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):618,032
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):47,792
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):41,285
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):21,330
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(5,567)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(0.07)
11.Total assets end of the period (thousand NTD):6,819,111
12.Total liabilities end of the period
(thousand NTD):1,645,636
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,795,493
14.Any other matters that need to be specified:None

Speech Date

2024/11/11

Theme

Announcement pursuant to §22 I subpara. 2&3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2024-11-11

Describe

1.Date of occurrence of the event:2024/11/11
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name:Coaim Information Technology Co., Ltd.
(2)Relationship with lender:
Lender:Cowealth Medical China Co., Ltd.
The company's subsidiaries directly and indirectly hold 100% of the shares
(3)Lending limit (thousand NTD):2,106,410
(4)Starting outstanding balance (thousand NTD):0
(5)New loan (thousand NTD):179,612
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:179,612
(8)Reason for new loan (thousand NTD):working capital
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):147,103
(2)Cumulative gains/losses (thousand NTD):1,675
5.Method of calculation of interest:4.35%
6.For repayment, the(1)Condition(2)Date:
(1)Condition:None
(2)Date:One year starting on the first payment date
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):1,962,621
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.70
9.Sources of funds for the company to extend monetary
loans to others:Financial institutions and parent company
10.Any other matters that need to be specified:
The original lending limit is due to expire on November 28, 2024.
It has been early repayment and cancelled before the Board of Directors.
This is a new application for a lending limit.

Speech Date

2024/11/11

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2024-11-11

Describe

1.Date of occurrence of the event:2024/11/11
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name:Colab Reserch & Development Inc.
(2)Relationship with lender:
Lender:Coaim Information Technology Co., Ltd.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD):327,057
(4)Starting outstanding balance (thousand NTD):0
(5)New loan (thousand NTD):134,709
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:134,709
(8)Reason for new loan (thousand NTD):working capital
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):41,972
(2)Cumulative gains/losses (thousand NTD):21,603
5.Method of calculation of interest:4.35%
6.For repayment, the(1)Condition(2)Date:
(1)Condition:None
(2)Date:One year starting on the first payment date
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):1,962,621
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.70
9.Sources of funds for the company to extend monetary
loans to others:Subsidiary’s own funds
10.Any other matters that need to be specified:
The original lending limit is due to expire on January 2, 2025.
It has been early repayment and cancelled before the Board of Directors.
This is a new application for a lending limit.

Speech Date

2024/11/11

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2024-11-11

Describe

1.Date of occurrence of the event:2024/11/11
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name:Cowealth Medical Shanghai Co., Ltd.
(2)Relationship with lender:
Lender:Cowealth Medical China Co., Ltd.
The company's subsidiaries directly and indirectly hold 100% of the shares
(3)Lending limit (thousand NTD):2,106,410
(4)Starting outstanding balance (thousand NTD):0
(5)New loan (thousand NTD):89,806
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:89,806
(8)Reason for new loan (thousand NTD):working capital

(1)Name:Cowealth Medical Shanghai Co., Ltd.
(2)Relationship with lender:
Lender:Coaim Information Technology Co., Ltd.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD):327,057
(4)Starting outstanding balance (thousand NTD):0
(5)New loan (thousand NTD):89,806
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:89,806
(8)Reason for new loan (thousand NTD):working capital
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):22,089
(2)Cumulative gains/losses (thousand NTD):35,615
5.Method of calculation of interest:4.35%
6.For repayment, the(1)Condition(2)Date:
(1)Condition:None
(2)Date:One year starting on the first payment date
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):1,962,621
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.70
9.Sources of funds for the company to extend monetary
loans to others:Subsidiary’s own funds. financial institutions and
parent company
10.Any other matters that need to be specified:
The original lending limit was due to expire on November 9, 2024.
It has been early repayment and cancelled before the Board of Directors.
This is a new application for a lending limit.

Speech Date

2024/11/11

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2024-11-11

Describe

1.Date of occurrence of the event:2024/11/11
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name:Cowealth Holding Co., Ltd.
(2)Relationship with lender:
Lender:COWEALTH HOLDING CO.,LTD.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD):292,069
(4)Starting outstanding balance (thousand NTD):98,787
(5)New loan (thousand NTD):98,787
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:197,574
(8)Reason for new loan (thousand NTD):working capital
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):751,205
(2)Cumulative gains/losses (thousand NTD):1,439,340
5.Method of calculation of interest:
The maximum interest rate on short-term debt from financial institutions
6.For repayment, the(1)Condition(2)Date:
(1)Condition:None
(2)Date:One year starting on the first payment date
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):1,962,621
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.70
9.Sources of funds for the company to extend monetary
loans to others:Subsidiary’s own funds
10.Any other matters that need to be specified:
The original lending limit is due to expire on January 19, 2025.
It has been early repayment and cancelled before the Board of Directors.
This is a new application for a lending limit.

Speech Date

2024/11/11

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2024-11-11

Describe

1.Date of occurrence of the event:2024/11/11
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name:Royal Seal Holding Co., Ltd.
(2)Relationship with lender:
Lender:Cowealth Medical China Co., Ltd.
The company's subsidiaries directly and indirectly hold 100% of the shares
(3)Lending limit (thousand NTD):2,106,410
(4)Starting outstanding balance (thousand NTD):0
(5)New loan (thousand NTD):179,612
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:179,612
(8)Reason for new loan (thousand NTD):working capital
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):795,070
(2)Cumulative gains/losses (thousand NTD):-135,356
5.Method of calculation of interest:4.35%
6.For repayment, the(1)Condition(2)Date:
(1)Condition:None
(2)Date:One year starting on the first payment date
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):1,962,621
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.70
9.Sources of funds for the company to extend monetary
loans to others:Financial institutions and parent company
10.Any other matters that need to be specified:
The original lending limit was due to expire on November 9, 2024.
It has been early repayment and cancelled before the Board of Directors.
This is a new application for a lending limit.

Speech Date

2024/11/11

Theme

Announcement pursuant to §25 I subpara. 4 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2024-11-11

Describe

1.Date of occurrence of the event:2024/11/11
2.For the company for whom the endorsements
/guarantees were made(1)Company name(2)Its
relationship with the Company providing endorsements/
guarantees(3)The ceiling on the endorsements/
guarantees (thousand NTD)(4)The original amount of
endorsements/guarantees (thousand NTD)(5)the amount
of the current additional endorsements/guarantees
(thousand NTD)(6)The amount of endorsements/guarantees
as of the dateof occurrence (thousand NTD)(7)The actual
loaned amount of the company for whom endorsements/
guarantees were made (thousand NTD)(8)The reason for
the current additional endorsements/guarantees:
(1)Company name:Royal Seal Holding Co., Ltd.
(2)Its relationship with the Company providing endorsements/guarantees:
The company providing endorsements/guarantees: Cowealth Medical China
Co., Ltd.
The company's subsidiaries directly and indirectly hold 100%
of the shares
(3)The ceiling on the endorsements/guarantees (thousand NTD):5,590,985
(4)The original amount of endorsements/guarantees (thousand NTD):0
(5)the amount of the current additional endorsements/guarantees
(thousand NTD):898,060
(6)The amount of endorsements/guarantees as of the dateof occurrence
(thousand NTD):898,060
(7)The actual loaned amount of the company for whom endorsements/guarantees
were made (thousand NTD):0
(8)The reason for the current additional endorsements/guarantees:
working capital
3.For collaterals provided by the company for
whom the endorsements/guarantees were made, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial statements of the company
for whom the endorsements/guarantees were made, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):795,070
(2)Cumulative gains/losses (thousand NTD):-135,356
5.For termination of endorsement/guarantee obligations, the
(1)Condition(2)Date:
(1)Condition:Contract expires
(2)Date:Contract expires
6.The total amount of the ceiling on endorsements/
guarantees (thousand NTD):13,977,462
7.The total amount of endorsements/guarantees as of
the date of occurrence (thousand NTD):2,101,046
8.The amount of endorsements/guarantees provided by
A as a percentage of the public company’s net worth
on the latest financial report as of the date of
occurrence:0.75
9.The aggregate amount of long-term investments,
endorsements/guarantees, and monetary loans extended
to others as a percentage of the public company’s net
worth on the latest financial statements:1.46
10.Any other matters that need to be specified:
The original lending limit was due to expire on November 9, 2024.

Speech Date

2024/11/01

Theme

Announcement for the Board of Directors meeting date of 2024Q3 Consolidated Financial Report

Fact Date

2024-11-01

Describe

1.Date of a notice of the board of directors meeting is issued:2024/11/01
2.Expected date of the board of directors meeting is convened:2024/11/11
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors:2024Q3 consolidated financial report
4.Any other matters that need to be specified:None

Speech Date

2024/10/30

Theme

(Retrospective Announcement) Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. to hold 2024 third quarter performance conference

Fact Date

2024-10-29

Describe

1.Date and time that the Company disclose its financial
or business information to the public:2024/10/29
2.Location that the Company disclose its financial or
business information to the public:Web conference
3.Financial/Business data to be disclosed:
Operating results and financial position for 2024 third quarter
4.Content of press release, if provided:NA
5.Any other matters that need to be specified:
Date and time of conference：2024/10/29(Tuesday) 11:30-12:30
Online platform：https://www.ir-online.cn
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2024/10/23

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2024-10-23

Describe

1.Date of occurrence of the event:2024/10/23
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 55.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
1、Resolutions Regarding the 2024 Third Quarter Report of the Company
2、Resolutions Regarding the proposal to adjust the Board Strategy Committee
into the Board Strategy and ESG Committee and to amend the related
procedural rules
3、Resolutions Regarding the use of notes and self-owned funds to pay for
the capital needed for fundraising projects and the replacement of this
amount with an equivalent amount of raised funds
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2024/09/10

Theme

Announcement of the important resolutions of 2024 1st special shareholders’ meeting

Fact Date

2024-09-10

Describe

1.Date of the special shareholders' meeting:2024/09/10
2.Important resolutions:
I. Election matters: By-election for independent directors
II. Other Proposals: Removal of the non-compete clause for by-election of
independent directors
3.Any other matters that need to be specified:None

Speech Date

2024/09/10

Theme

Announcement of the list of by-elected independent directors of 2024 1st special shareholders’ meeting

Fact Date

2024-09-10

Describe

1.Date of occurrence of the change:2024/09/10
2.Elected or changed position (Please enter institutional director,
institutional supervisor, independent director, natural-person director or
natural-person supervisor):independent director
3.Title, name and nationality of the previous position holder:NA
4.Resume of the previous position holder:NA
5.Title, name and nationality of the new position holder:
independent director, CHEN,SHU-HUA, ROC
6.Resume of the new position holder:
Accounting manager of CEN TECH PTE LTD. TAIWAN BRANCH (SINGAPORE)
7.Circumstances of change (Please enter “resignation”, “dismissal”,
“term expired”, “death” or “new appointment”):new appointment
8.Reason for the change:One by-elected independent directors at
special shareholders’ meeting.
9.Number of shares held by the new position holder when elected:0 share
10.Original term (from __________ to __________):2023/05/24~2026/05/23
11.Effective date of the new appointment:2024/09/10
12.Turnover rate of directors of the same term:1/9
13.Turnover rate of independent directors of the same term:1/4
14.Turnover rate of supervisors of the same term:NA
15.Change in one-third or more of directors (Please enter “Yes” or
“No”):No
16.Directors with a registered household address in ROC.does not
exceed 1/2 of the existing directors after the change (Please enter
“Yes”or ”No”,if ”yes”, please indicate the countermeasures):No
17.Only less than 2 independent directors with a registered
household address in ROC.after the change (Please enter ”Yes”
or “No”,if ”yes”, please indicate the countermeasures):No
18.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):None

Speech Date

2024/09/10

Theme

Announcement of removal of the non-compete clause for independent directors of 2024 1st special shareholders’ meeting

Fact Date

2024-09-10

Describe

1.Date of the shareholders' meeting resolution:2024/09/10
2.Name and title of the managerial officer with permission
to engage in competitive conduct:CHEN,SHU-HUA, independent director
3.Items of competitive conduct in which the officer is
permitted to engage:
Accounting manager of CEN TECH PTE LTD. TAIWAN BRANCH (SINGAPORE)
4.Period of permission to engage in the competitive conduct:
For the duration of serving as an independent director
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
The number of voting rights of shareholders present at the time of voting
is 46,427,512.
The approval rights are 45,526,329, accounting for 98.05% of the
total rights.
The number of for votes exceeded the statutory threshold, and the proposed
change was passed.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter “N/A” below):NA
7.Company name of the mainland China enterprise and the
officer’s position in the enterprise:NA
8.Address of the mainland China enterprise:NA
9.Operations of the mainland China enterprise:NA
10.Impact on the company’s finance and business:NA
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:NA
12.Any other matters that need to be specified:None

Speech Date

2024/09/10

Theme

Announcement of changes in member of Audit Committee

Fact Date

2024-09-10

Describe

1.Date of occurrence of the change:2024/09/10
2.Name of the functional committees:Audit Committee
3.Name of the previous position holder:NA
4.Resume of the previous position holder:NA
5.Name of the new position holder:CHEN,SHU-HUA
6.Resume of the new position holder:CHEN,SHU-HUA,
Accounting manager of CEN TECH PTE LTD. TAIWAN BRANCH (SINGAPORE)
7.Circumstances of change (Please enter “resignation”, “dismissal”,
“term expired”, “death” or “new appointment”):new appointment
8.Reason for the change:One by-elected independent directors at
special shareholders’ meeting.
9.Original term (from __________ to __________):2023/05/24~2026/05/23
10.Effective date of the new member:2024/09/10
11.Any other matters that need to be specified:None

Speech Date

2024/09/04

Theme

Announcement of the corrections of part of information in additional disclosures for 2024Q2 consolidated financial report

Fact Date

2024-09-04

Describe

1.Date of occurrence of the event:2024/09/04
2.Company name:Cowealth Medical Holding Co., Ltd.
3.Relationship to the Company (please enter ”head
office” or ”subsidiaries”):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:Announcement of the corrections of part of information
in additional disclosures for 2024Q2 consolidated financial report
6.Information items/ statements to be corrected:
part of information in additional disclosures
7.Amounts/ contents/ number of page to be corrected:Note6(5) Inventory/P.15
8.Amounts/ contents/ number of page after correction:Note6(5) Inventory/P.15
9.Countermeasures:Publish material information and upload the corrected
content to the Public Information Observatory Financial Report Update
(Supplement) Positive area.
10.Any other matters that need to be specified:
This update (supplement) has no impact on the company's consolidated profits
and losses.

Speech Date

2024/09/02

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. to hold 2024 semi-annual performance conference

Fact Date

2024-09-11

Describe

1.Date and time that the Company disclose its financial
or business information to the public:2024/09/11
2.Location that the Company disclose its financial or
business information to the public:Web conference
3.Financial/Business data to be disclosed:
Operating results and financial position for 2024 semi-annual
4.Content of press release, if provided:NA
5.Any other matters that need to be specified:
Date and time of conference：2024/9/11(Wednesday) 11:30-12:30
Online platform：https://www.ir-online.cn
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2024/08/28

Theme

Announcement of the Board of Directors approved the consolidated financial statements for the second quarter of 2024

Fact Date

2024-08-28

Describe

1.Date of the board of directors submitted or approved:2024/08/28
2.Date of the audit committee approved:2024/08/28
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2024/01/01~2024/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):2,130,528
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):426,054
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):44,113
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):40,998
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):23,660
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):331
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0
11.Total assets end of the period (thousand NTD):6,810,263
12.Total liabilities end of the period
(thousand NTD):1,659,068
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,788,106
14.Any other matters that need to be specified:None

Speech Date

2024/08/28

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2024-08-28

Describe

1.Date of occurrence of the event:2024/08/28
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 55.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
1、Resolutions regarding the 2024 semi-annual report and its summary
of the company
2、Resolutions regarding the special report on the storage and actual use
of funds raised during the first half of 2024
3、Resolutions regarding the proposal to utilize part of the idle raised
funds for cash management
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2024/08/28

Theme

Announcement pursuant to §22 I subpara. 1 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2024-08-28

Describe

1.Date of occurrence of the event:2024/08/28
2.The public company or its subsidiaries for which
the amount of monetary loans extended to others reaches
20 percent or more of their net worth on the latest
financial statements(1)Name of funding recipient
(2)Relationship with lender(3)Lending limit
(thousand NTD)(4)Outstanding balance (thousand NTD)
up to the date of occurrence(5)Reason for lending
up to the date of occurrence:
(1)Name of funding recipient:Chuangjuhe (Shanghai) Information Technology
Co., Ltd.
(2)Relationship with lender:
Lender: Coaim Information Technology Co., Ltd.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD):352,137
(4)Outstanding balance (thousand NTD) up to the date of occurrence:9,070
(5)Reason for lending up to the date of occurrence:working capital
3.The total amount of monetary loans extended to others
as of the date of occurrence:1,940,159
4.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.70
5.Sources of funds for the company to extend monetary
loans to others:Subsidiary’s own funds
6.Any other matters that need to be specified:None

Speech Date

2024/08/28

Theme

Announcement pursuant to §25 I subpara. 4 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2024-08-28

Describe

1.Date of occurrence of the event:2024/08/28
2.For the company for whom the endorsements
/guarantees were made(1)Company name(2)Its
relationship with the Company providing endorsements/
guarantees(3)The ceiling on the endorsements/
guarantees (thousand NTD)(4)The original amount of
endorsements/guarantees (thousand NTD)(5)the amount
of the current additional endorsements/guarantees
(thousand NTD)(6)The amount of endorsements/guarantees
as of the dateof occurrence (thousand NTD)(7)The actual
loaned amount of the company for whom endorsements/
guarantees were made (thousand NTD)(8)The reason for
the current additional endorsements/guarantees:
(1)Company name:Royal Seal Holding Co., Ltd.
(2)Its relationship with the Company providing endorsements/guarantees:
The company providing endorsements/guarantees: Cowealth Medical Holding
Co., Ltd.
The company's subsidiaries directly and indirectly hold more than 50%
of the shares
(3)The ceiling on the endorsements/guarantees (thousand NTD):5,576,211
(4)The original amount of endorsements/guarantees (thousand NTD):493,961
(5)the amount of the current additional endorsements/guarantees
(thousand NTD):346,496
(6)The amount of endorsements/guarantees as of the dateof occurrence
(thousand NTD):840,457
(7)The actual loaned amount of the company for whom endorsements/guarantees
were made (thousand NTD):287,134
(8)The reason for the current additional endorsements/guarantees:
Signing a new bank contract and renewing the old credit limit
3.For collaterals provided by the company for
whom the endorsements/guarantees were made, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial statements of the company
for whom the endorsements/guarantees were made, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):795,070
(2)Cumulative gains/losses (thousand NTD):-131,965
5.For termination of endorsement/guarantee obligations, the
(1)Condition(2)Date:
(1)Condition:Maturity of bank financing
(2)Date:Maturity of bank financing
6.The total amount of the ceiling on endorsements/
guarantees (thousand NTD):13,940,527
7.The total amount of endorsements/guarantees as of
the date of occurrence (thousand NTD):2,281,017
8.The amount of endorsements/guarantees provided by
A as a percentage of the public company’s net worth
on the latest financial report as of the date of
occurrence:0.82
9.The aggregate amount of long-term investments,
endorsements/guarantees, and monetary loans extended
to others as a percentage of the public company’s net
worth on the latest financial statements:1.52
10.Any other matters that need to be specified:
Some of the bank lines were not yet expired, there is a situation
where the endorsement and guarantee lines were double-calculated.

Speech Date

2024/08/20

Theme

Announcement for the Board of Directors meeting date of 2024Q2 Consolidated Financial Report

Fact Date

2024-08-20

Describe

1.Date of a notice of the board of directors meeting is issued:2024/08/20
2.Expected date of the board of directors meeting is convened:2024/08/28
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors:2024Q2 consolidated financial report
4.Any other matters that need to be specified:None

Speech Date

2024/08/09

Theme

Announcement of the partial supplement or correction of the 2023 Annual Shareholders' Meeting Report

Fact Date

2024-08-09

Describe

1.Date of receipt of letter from TPEx to request
supplement or correction:2024/08/05
2.Deadline imposed for supplement or correction:2024/08/09
3.Content of supplement or correction:
Partial supplement or correction of the 2023 Annual Shareholders'
Meeting Report.
Chinese Version: Pages 42.1-42.2
English Version: Pages 45.1-45.2
4.Countermeasures:
Re-upload revised the Annual Report (version revised upon shareholders’
meeting) to the Market Observation Post System.
5.Any other matters that need to be specified:None

Speech Date

2024/07/12

Theme

Announcement of the corrections of the consolidated financial statements for the year of 2023 and 2024Q1

Fact Date

2024-07-12

Describe

1.Date of occurrence of the event:2024/07/12
2.Company name:Cowealth Medical Holding Co., Ltd.
3.Relationship to the Company (please enter ”head
office” or ”subsidiaries”):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:Announcement of the corrections of the consolidated
financial statements for the year of 2023 and 2024Q1.
6.Information items/ statements to be corrected:Consolidated Balance Sheets,
Consolidated Statements of Comprehensive Income, Consolidated Statements of
Changes in Equity, Consolidated Statements of Cash Flows and Notes to
Consolidated Financial Statements for the year of 2023 and 2024Q1.
7.Amounts/ contents/ number of page to be corrected:
2023.12.31
Consolidated Balance Sheets
for the year of 2023 /P.4 After correction Before correction
Inventories 838,989 850,989
Total current assets 5,659,741 5,671,741
Total assets 6,623,374 6,635,374
Unappropriated retained earnings 495,973 502,573
Total retained earnings 919,939 926,539
Stockholder' equity attributable to parent 2,712,284 2,718,884
Non-controlling interests 2,304,154 2,309,554
Total stockholder' equity 5,016,438 5,028,438
Total liabilities and stockholder' equity 6,623,374 6,635,374

2023
Consolidated Statements of
Comprehensive Income for
the year of 2023 /P.5 After correction Before correction
Operating costs 3,828,116 3,816,116
Gross Profit 984,453 996,453
Operating Income 264,172 276,172
Profit from continuing operations
before tax 258,310 270,310
Profit 138,360 150,360
Comprehensive income 48,736 60,736
Profit attributable to
owners of the parent 49,109 55,709
Profit attributable to
non-controlling interests 89,251 94,651
Comprehensive income attributable to
owners of the parent 814 7,414
Comprehensive income attributable to
non-controlling interests 47,922 53,322
Basic earnings per share (NT dollars) 0.63 0.72
Diluted earnings per share (NT dollars) 0.63 0.72

Correction of Consolidated Statements of Changes in Equity(P.6), Consolidated
Statements of Cash Flows(P.7), and Note 6(5) Inventories(P.26), Note 6(10)
Earnings per share(P.37), Note 13(1)(i). Guarantees and endorsements for
other parties(P.50-51), (x) Business relationships and significant
intercompany transactions(P.52-53), Note 13(3) Information on investment in
mainland China (ii) Limitation on investment in mainland China(P.56),
Note 14(2) Segment information(P.57-58)
=============================================================================
2024.3.31 2023.12.31
Consolidated Balance After Before After Before
Sheets for 2024Q1/P.4 correction correction correction correction
Inventories 876,173 888,173 838,989 850,989
Total current assets 5,896,570 5,908,570 5,659,741 5,671,741
Total assets 6,805,988 6,817,988 6,623,374 6,635,374
Unappropriated retained
earnings 501,217 507,817 495,973 502,573
Total retained earnings 925,183 931,783 919,939 926,539
Stockholder' equity
attributable to parent 2,789,108 2,795,708 2,712,284 2,718,884
Non-controlling interests 2,377,460 2,382,860 2,304,154 2,309,554
Total stockholder' equity 5,166,568 5,178,568 5,016,438 5,028,438
Total liabilities and
stockholder' equity 6,805,988 6,817,988 6,623,374 6,635,374

Correction of Consolidated Statements of Changes in Equity(P.6), and
Note 6(5) Inventories(P.15), Note 13(1)(i). Guarantees and endorsements
for other parties(P.35-36), (x) Business relationships and significant
intercompany transactions(P.37), Note 13(3) Information on investment
in mainland China (ii) Limitation on investment in mainland China(P.40),
Note 14(1) Segment information(P.42)
8.Amounts/ contents/ number of page after correction:Same as above description
9.Countermeasures:Publish material information and upload the corrected
content to the Public Information Observatory Financial Report Update
(Supplement) Positive area Publish important information and re-upload
it on the Public Information Observatory.
10.Any other matters that need to be specified:None

Speech Date

2024/06/19

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2024-06-19

Describe

1.Date of occurrence of the event:2024/06/19
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 55.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
1、Resolutions Regarding the Change in Accounting Estimates
2、Resolutions Regarding the Adjustment of Members to the Second
Board of Directors Audit Committee
3、Resolutions Regarding the Appointment of the Board Secretary
4、Resolutions Regarding the Modification of Part of the Raised Funds
Account
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2024/06/13

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the ex-dividend record date and the date of cash dividend distribution

Fact Date

2024-06-13

Describe

1.Date of the resolution by the board of directors or shareholders' meeting
or decision by the Company:2024/06/13
2.Type of ex-rights or ex-dividend (please enter: “Ex-rights”,
”Ex-dividend”, or ”Ex-rights and dividend”):Ex-dividend
3.Type and monetary amount of dividend distribution:
Cash Dividends RMB23,883,157.98(tax included)
4.Ex-rights (ex-dividend) trading date:2024/06/21
5.Last date before book closure:NA
6.Book closure starting date:NA
7.Book closure ending date:NA
8.Ex-rights (ex-dividend) record date:2024/06/20
9.Deadline for applying the conversion of the debt voucher:NA
10.The closure period for the conversion of the debt voucher will
start from the date:NA
11.The closure period for the conversion of the debt voucher
will end on the date:NA
12.Payment date of cash dividend distribution:2024/06/21
13.Any other matters that need to be specified:
This profit distribution plan was approved at the 2023 annual shareholders'
meeting on 2024/4/29. The shareholder list as of the close of trading on
2024/6/20 is used as the basis for dividend distribution, the cash dividend
distribution date is 2024/6/21.
The profit distribution plan is based on a share capital of 398,052,633
shares, cash dividend is RMB0.06 per share(tax included), total of
RMB23,883,157.98(tax included).

Speech Date

2024/06/07

Theme

Announcement of the resolution by the Board of Directors for the ex-dividend record date and the date of cash dividend distribution

Fact Date

2024-06-07

Describe

1.Date of the resolution by the board of directors or
shareholders’ meeting, or of the decision by the company:2024/06/07
2.Type (ex-rights or ex-dividend) (please write ”Ex-rights”,
”Ex-dividend”, or ”Ex-rights and dividend”):Ex-dividend
3.Type and monetary amount of dividend distribution:
The cash dividend is NT$0.4 per share, total of NT$30,979,819
4.Ex-rights (Ex-dividend) date:2024/06/27
5.Last date before book closure:2024/06/30
6.Book closure starting date:2024/07/01
7.Book closure ending date:2024/07/05
8.Ex-rights (Ex-dividend) record date:2024/07/05
9.Deadline for applying the conversion of the debt voucher:NA
10.The closure period for the conversion of the debt voucher will
start from the date:NA
11.The closure period for the conversion of the debt voucher will
end on the date:NA
12.Payment date of cash dividend distribution:2024/08/02
13.Any other matters that need to be specified:
The annual general shareholders’ meeting on 2024/5/29 resolved to
authorize the Board of Directors to establish the ex-dividend date
and related matters. The Board of Directors on 2024/6/7 is decided
that the cash dividend is proposed to be distributed on 2024/8/2,
through stock registrar and transfer agent. In the event of special
circumstances necessitating an adjustment in the distribution, it is
proposed to authorize the chairman of the Board to handle the matter
with full authority.

Speech Date

2024/06/07

Theme

Announcement of convening the 2024 special Shareholders' Meeting

Fact Date

2024-06-07

Describe

1.Date of the board of directors resolution:2024/06/07
2.Extraordinary shareholders' meeting date:2024/09/10
3.Extraordinary shareholders'' meeting location:Cowealth Center of 23F, No.76,
Sec. 2, Dunhua S. Rd., Da' an Dist., Taipei City 106485, Taiwan (R.O.C.)
4.Special shareholders meeting will be held by means of
(physical shareholders meeting/ visual communication
assisted shareholders meeting /visual communication
shareholders meeting):physical shareholders meeting
5.Cause for convening the meeting I.Reported matters:None
6.Cause for convening the meeting II.Acknowledged matters:None
7.Cause for convening the meeting III.Matters for Discussion:None
8.Cause for convening the meeting IV.Election matters:
By-election for independent directors
9.Cause for convening the meeting V.Other Proposals:
Removal of the non-compete clause for by-election of independent directors
10.Cause for convening the meeting VI.Extemporary Motions:None
11.Book closure starting date:2024/08/12
12.Book closure ending date:2024/09/10
13.Any other matters that need to be specified:
(1)Acceptance period: from June 14, 2024 to June 24, 2024.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd., Da’an Dist.,
Taipei City 106485, Taiwan (R.O.C.)

Speech Date

2024/05/29

Theme

Announcement of the important resolutions of 2024 annual general shareholders’ meeting

Fact Date

2024-05-29

Describe

1.Date of the shareholders' meeting:2024/05/29
2.Important resolutions I.Profit distribution/deficit compensation:
Approved the 2023 earnings distribution
3.Important resolutions II.Amendments of the company charter:
Approved the amendment to the ”Articles of Association”
4.Important resolutions III.Business report and financial statements:
Approved the 2023 annual financial statements and business report
5.Important resolutions IV.Election for directors and supervisors:None
6.Important resolutions V.Other matters:
(1)Approved the amendment to the ”Procedures for Asset Acquisition &
Disposal”
(2)Approved the amendment to the ”Rules of Procedure for Shareholders
Meetings”
(3)Approved the amendment to the ”Procedures for Election of Directors”
(4)Approved the authorization of the Board of Directors to resolve to
amend the Board of Directors’ Rules of Procedure
7.Any other matters that need to be specified:None

Speech Date

2024/05/29

Theme

Announcement of changes in convener of Audit Committee

Fact Date

2024-05-29

Describe

1.Date of occurrence of the change:2024/05/29
2.Name of the functional committees:Audit Committee
3.Name of the previous position holder:TSAI,YANN-CHING
4.Resume of the previous position holder:TSAI,YANN-CHING,
Professor, Department of Accounting, National Taiwan University
5.Name of the new position holder:CHEN,KUN-CHIH
6.Resume of the new position holder:CHEN,KUN-CHIH,
Associate Professor, Department of Accounting, National Taiwan University
7.Circumstances of change (Please enter “resignation”, “dismissal”,
“term expired”, “death” or “new appointment”):new appointment
8.Reason for the change:The original convener of Audit Committee has resigned,
and the committee members nominate new one.
9.Original term (from __________ to __________):2023/05/24~2026/05/23
10.Effective date of the new member:2024/05/29
11.Any other matters that need to be specified:None

Speech Date

2024/05/15

Theme

Announcement about resignation of the independent director

Fact Date

2024-05-15

Describe

1.Date of occurrence of the change:2024/05/15
2.Elected or changed position (Please enter institutional director,
institutional supervisor, independent director, natural-person director or
natural-person supervisor):independent director
3.Title, name and nationality of the previous position holder:
independent director, TSAI,YANN-CHING, ROC
4.Resume of the previous position holder:
independent director, TSAI,YANN-CHING,
Professor, Department of Accounting, National Taiwan University
5.Title, name and nationality of the new position holder:NA
6.Resume of the new position holder:NA
7.Circumstances of change (Please enter “resignation”, “dismissal”,
“term expired”, “death” or “new appointment”):resignation
8.Reason for the change:personal reason
9.Number of shares held by the new position holder when elected:NA
10.Original term (from __________ to __________):2023/05/24~2026/05/23
11.Effective date of the new appointment:NA
12.Turnover rate of directors of the same term:1/9
13.Turnover rate of independent directors of the same term:1/4
14.Turnover rate of supervisors of the same term:NA
15.Change in one-third or more of directors (Please enter “Yes” or
“No”):No
16.Directors with a registered household address in ROC.does not
exceed 1/2 of the existing directors after the change (Please enter
“Yes”or ”No”,if ”yes”, please indicate the countermeasures):No
17.Only less than 2 independent directors with a registered
household address in ROC.after the change (Please enter ”Yes”
or “No”,if ”yes”, please indicate the countermeasures):No
18.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
Effective date of resignation is 2024/05/15.

Speech Date

2024/05/15

Theme

Announcement about resignation of member and convener of Audit Committee

Fact Date

2024-05-15

Describe

1.Date of occurrence of the change:2024/05/15
2.Name of the functional committees:Audit Committee
3.Name of the previous position holder:TSAI,YANN-CHING
4.Resume of the previous position holder:TSAI,YANN-CHING,
Professor, Department of Accounting, National Taiwan University
5.Name of the new position holder:NA
6.Resume of the new position holder:NA
7.Circumstances of change (Please enter “resignation”, “dismissal”,
“term expired”, “death” or “new appointment”):resignation
8.Reason for the change:personal reason
9.Original term (from __________ to __________):2023/05/24~2026/05/23
10.Effective date of the new member:NA
11.Any other matters that need to be specified:
Effective date of resignation is 2024/05/15.

Speech Date

2024/05/13

Theme

Announcement of the Board of Directors approved the consolidated financial statements for the first quarter of 2024

Fact Date

2024-05-13

Describe

1.Date of the board of directors submitted or approved:2024/05/13
2.Date of the audit committee approved:2024/05/13
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2024/01/01~2024/03/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):1,046,246
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):228,437
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):35,386
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):36,966
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):22,021
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):5,244
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.07
11.Total assets end of the period (thousand NTD):6,817,988
12.Total liabilities end of the period
(thousand NTD):1,639,420
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,795,708
14.Any other matters that need to be specified:None

Speech Date

2024/05/03

Theme

Announcement for the Board of Directors meeting date of 2024Q1 Consolidated Financial Report

Fact Date

2024-05-03

Describe

1.Date of a notice of the board of directors meeting is issued:2024/05/03
2.Expected date of the board of directors meeting is convened:2024//05/13
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors:2024Q1 consolidated financial report
4.Any other matters that need to be specified:None

Speech Date

2024/04/29

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2024-04-29

Describe

1.Date of occurrence of the event:2024/04/29
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 55.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
Resolutions Regarding the 2024 First Quarter Report of the Company
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2024/04/29

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions of 2023 annual general shareholders’ meeting

Fact Date

2024-04-29

Describe

1.Date of the shareholders' meeting:2024/04/29
2.Important resolutions I.Profit distribution/deficit compensation:
Approval of the ”Resolutions Regarding the Proposed Profit Distribution Plan
for the Year 2023”
3.Important resolutions II.Amendments of the company charter:None
4.Important resolutions III.Business report and financial statements:
Approval of the”Resolutions Regarding the 2023 Financial Statements Report
of the Company”
5.Important resolutions IV.Election for directors and supervisors:None
6.Important resolutions V.Other matters:
(1)Approval of the ”Resolutions Regarding the 2023 Board of Directors'
Work Report of the Company”
(2)Approval of the ”Resolutions Regarding the 2023 Independent Directors'
Performance Report of the Company”
(3)Approval of the ”Resolutions Regarding the 2023 Supervisory Board's
Work Report of the Company”
(4)Approval of the ”Resolutions Regarding the 2023 Annual Report and
its Summary of the Company”
(5)Approval of the ”Resolutions Regarding the Re-appointment of the Audit
Institution for the Year 2024”
(6)Approval of the ”Resolutions Regarding the Plan for the Guarantee Quota
for the Year 2024 of the Company”
7.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2024/04/11

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. to hold 2023 annual performance conference

Fact Date

2024-04-19

Describe

1.Date and time that the Company disclose its financial
or business information to the public:2024/04/19
2.Location that the Company disclose its financial or
business information to the public:Web conference
3.Financial/Business data to be disclosed:
Operating results and financial position for the financial year 2023
4.Content of press release, if provided:NA
5.Any other matters that need to be specified:
Date and time of conference：2024/4/19(Friday) 11:30-12:30
Online platform：https://www.ir-online.cn
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2024/03/22

Theme

Announcement of the Board of Directors approved the consolidated financial statements for the year of 2023

Fact Date

2024-03-22

Describe

1.Date of the board of directors submitted or approved:2024/03/22
2.Date of the audit committee approved:2024/03/22
3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX): 2023/01/01~2023/12/31
4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):4,812,569
5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):996,453
6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):276,172
7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):270,310
8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):150,360
9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):55,709
10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):0.72
11.Total assets end of the period (thousand NTD):6,635,374
12.Total liabilities end of the period (thousand NTD):1,606,936
13.Equity attributable to owners of parent end of the period (thousand NTD):2,718,884
14.Any other matters that need to be specified:None

Speech Date

2024/03/22

Theme

Announcement of the resolution by the Board of Directors to distribute dividends

Fact Date

2024-03-22

Describe

1.Date of the board of directors resolution:2024/03/22
2.Year or quarter which dividends belong to :2023
3.Period which dividends belong to:2023/01/01~2023/12/31
4.Appropriations of earnings in cash dividends to shareholders (NT$ per share):0.4
5.Cash dividends distributed from legal reserve and capital reserve to shareholders (NT$ per share):0
6.Total amount of cash dividends to shareholders (NT$):30,979,819
7.Appropriations of earnings in stock dividends to shareholders (NT$ per share):0
8.Stock dividends distributed from legal reserve and capital reserve to shareholders (NT$ per share):0
9.Total amount of stock dividends to shareholders (shares):0
10.Any other matters that need to be specified:None
11.Per value of common stock:NT$10

Speech Date

2024/03/22

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2024-03-22

Describe

1.Date of occurrence of the event:2024/03/22
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 55.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC for the resolutions by the Board of Directors
1、Resolutions Regarding the 2023 Annual Report and its Summary of the Company
2、Resolutions Regarding the 2023 Board of Directors' Work Report of the Company
3、Resolutions Regarding the 2023 Independent Directors' Performance Report of the Company
4、Resolutions Regarding the Self-assessment of Independence of Independent Directors
5、Resolutions Regarding the 2023 General Manager's Work Report of the Company
6、Resolutions Regarding the 2023 Audit Committee's Performance Report of the Company
7、Resolutions Regarding the 2023 Financial Statements Report of the Company
8、Resolutions Regarding the 2023 Internal Control Evaluation Report of the Company
9、Resolutions Regarding the Special Report on the Utilization of Raised Funds and its Actual Usage in 2023
10、Resolutions Regarding the 2024 Audit Plan of the Company
11、Resolutions Regarding the 2024 Compensation Plan for Senior Management Personnel of the Company
12、Resolutions Regarding the Entrustment of Temporary Idle Self-owned Funds for Financial Management by the Company
13、Resolutions Regarding the Proposed Profit Distribution Plan for the Year 2023
14、Resolutions Regarding the Performance Evaluation Report of the Accounting Firm for the Year 2023 and the Report on the Supervisory Duties Performed by the Audit Committee
15、Resolutions Regarding the Re-appointment of the Audit Institution for the Year 2024
16、Resolutions Regarding the Plan for the Guarantee Quota for the Year 2024 of the Company
17、Resolutions Regarding the Proposal to Convene the Annual Shareholders' Meeting of the Company for the Year 2023
6.Countermeasures:None
7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):For details of the above announcement, please refer to the disclosure website of Shanghai Stock Exchange:http://www.sse.com.cn/

Speech Date

2024/03/22

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolution by the Board of Directors to distribute dividends

Fact Date

2024-03-22

Describe

1.Date of the board of directors resolution:2024/03/22
2.Type and monetary amount of dividend distribution: Cash Dividends RMB$ 23,883,157.98(tax included)
3.Any other matters that need to be specified: For details of the above announcement, please refer to the disclosure website of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2024/03/22

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the 2024 shareholders' meeting location and related matters

Fact Date

2024-03-22

Describe

1.Date of the board of directors resolution:2024/03/22
2.General shareholders' meeting date:2024/04/29
3.General shareholders' meeting location: 20F Conference room of Guangqi Building, No. 456, Hongcao Rd., Xuhui Dist., Shanghai, China
4.Cause for convening the meeting I.Reported matters:None
5.Cause for convening the meeting II.Acknowledged matters:None
6.Cause for convening the meeting III, Matters for Discussion:
(1)Resolutions Regarding the 2023 Board of Directors' Work Report of the Company
(2)Resolutions Regarding the 2023 Independent Directors' Performance Report of the Company
(3)Resolutions Regarding the 2023 Supervisory Board's Work Report of the Company
(4)Resolutions Regarding the 2023 Annual Report and its Summary of the Company
(5)Resolutions Regarding the 2023 Financial Statements Report of the Company
(6)Resolutions Regarding the Proposed Profit Distribution Plan for the Year 2023
(7)Resolutions Regarding the Re-appointment of the Audit Institution for the Year 2024
(8)Resolutions Regarding the Plan for the Guarantee Quota for the Year 2024 of the Company
7.Cause for convening the meeting IV.Election matters:None
8.Cause for convening the meeting V.Other Proposals:None
9.Cause for convening the meeting VI.Extemporary Motions:None
10.Book closure starting date:NA
11.Book closure ending date:NA
12.Any other matters that need to be specified:For details of the above announcement, please refer to the disclosure website of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2024/03/15

Theme

Announcement of the Board of Directors approved the self-assessed consolidated financial statements for the year of 2023

Fact Date

2024-03-15

Describe

1.Date of the board of directors submitted or approved:2024/03/15
2.Date of the audit committee approved:NA
3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):2023/01/01~2023/12/31
4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):4,812,569
5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):996,453
6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):276,172
7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):270,310
8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):150,360
9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):55,709
10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):0.72
11.Total assets end of the period (thousand NTD):6,628,642
12.Total liabilities end of the period (thousand NTD):1,600,107
13.Equity attributable to owners of parent end of the period (thousand NTD):2,718,884
14.Any other matters that need to be specified:none

Speech Date

2024/03/08

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for obtaining business authorization from ViewRay Systems, Inc.

Fact Date

2024-03-08

Describe

1.Date of occurrence of the event:2024/03/08
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 55.00% shares
5.Cause of occurrence:
ViewRay Systems, Inc. (”ViewRay Systems”), the new entity responsible for the research and development, worldwide sales and after-sales of MRIdian
Linac equipment, has issued a authorization letter to Cowealth Medical China Co., Ltd. and its subsidiaries (hereinafter referred to as ”CMC”
or the ”Company”).
In the authorization, ViewRay Systems acknowledges that CMC, as its representative in Taiwan, Malaysia, Thailand, Singapore and Indonesia, is responsible for communicating with local government agencies regarding registration and license changes for all of its products and conducting business development, including the sales, delivery and service in these regions.
The Company's existing MRIdian Linac equipment will continue to be sold and service to customers within the scope of the authorization, which will have a positive impact on the Company's operations, following the granting of the aforementioned business authorization by ViewRay Systems, Inc.
In the course of the relevant business, there may be policy, market, economic and other unpredictable factors, there is a certain degree of risk and uncertainty, investors are advised to pay attention to the investment risk.
6.Countermeasures:None
7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):For details of the above announcement, please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2024/03/07

Theme

Board of Directors resolved to convene the 2024 Annual General Shareholders’ Meeting

Fact Date

2024-03-07

Describe

1.Date of the board of directors resolution:2024/03/07
2.General shareholders' meeting date:2024/05/29
3.General shareholders' meeting location:Cowealth Center of 23F, No. 76, Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106485, Taiwan (R.O.C.)
4.Shareholders meeting will be held by means of (physical shareholders meeting/ visual communication assisted shareholders meeting / visual communication shareholders meeting):physical shareholders meeting
5.Cause for convening the meeting I.Reported matters:
(1)2023 annual business report
(2)Audit Committee's review of the 2023 annual final accounting books and statements
(3)Report on 2023 employees' and directors' remuneration
(4)Report on 2023 director compensation
6.Cause for convening the meeting II.Acknowledged matters:
(1)2023 annual financial statements and business report
(2)2023 earnings distribution
7.Cause for convening the meeting III.Matters for Discussion:
(1)Amendments to the ”Articles of Association”
(2)Amendments to the ”Procedures for Asset Acquisition & Disposal”
(3)Amendments to the ”Rules of Procedure for Shareholders Meetings”
(4)Amendments to the ”Procedures for Election of Directors”
(5)Authorize the Board of Directors to resolve to amend the Board of Directors’ Rules of Procedure
8.Cause for convening the meeting IV.Election matters:None
9.Cause for convening the meeting V.Other Proposals:None
10.Cause for convening the meeting VI.Extemporary Motions:None
11.Book closure starting date:2024/03/31
12.Book closure ending date:2024/05/29
13.Any other matters that need to be specified:
(1)Acceptance period: from March 15, 2024 to March 25, 2024.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd., Da’an Dist. Taipei City 106485, Taiwan (R.O.C.)

Speech Date

2024/03/01

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for important personnel application for retirement

Fact Date

2024-02-29

Describe

1.Type of personnel changed (please enter:spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance
officer, chief information security officer,research and development officer, internal audit officer, or designated and non-designated representatives):vice president
2.Date of occurrence of the change:2024/02/29
3.Name, title, and resume of the previous position holder:TU,CHIA-HAI, vice president of Cowealth Medical China Co., Ltd.
4.Name, title, and resume of the new position holder:none
5.Type of change (please enter: ”resignation”,”position adjustment”, ”dismissal”, ”retirement ,”death” or ”new replacement”):retirement
6.Reason for the change:retirement
7.Effective date:2024/02/29
8.Any other matters that need to be specified:Mr. TU,CHIA-HAI will continue to serve as a consultant to the company after his resignation. For details of the above announcement, please refer to the disclosure website of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2024/03/01

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for financial officer application for retirement

Fact Date

2024-02-29

Describe

1.Type of personnel changed (please enter:spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance
officer, chief information security officer,research and development officer, internal audit officer, or designated and non-designated representatives):financial officer
2.Date of occurrence of the change:2024/02/29
3.Name, title, and resume of the previous position holder:ZHANG CHEN, financial officer of Cowealth Medical China Co., Ltd.
4.Name, title, and resume of the new position holder:To be approve by the Cowealth Medical China Co., Ltd. board of directors.
5.Type of change (please enter: ”resignation”,”position adjustment”, ”dismissal”, ”retirement”,”death” or ”new replacement”):retirement
6.Reason for the change:retirement
7.Effective date:2024/03/31
8.Any other matters that need to be specified:For details of the above announcement, please refer to the disclosure website of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2024/01/05

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions

Fact Date

2024-01-05

Describe

1.Date of the special shareholders' meeting:2024/01/05
2.Important resolutions:
(1) A proposal about revising and handling
the registration of industrial and commercial changes
(2) Approve the ”Proposal on Amending the Rules of Procedure
of the Board of Directors”
(3) Approve the ”Proposal on Amending the Rules of Procedure
of the Shareholders' Meeting”
(4) Approve the ”Proposal on Amending the Working System
of Independent Directors”
(5) Approve the ”Proposal on Changing the Implementation Methods
of Some Fund-raising Projects and Extension of Fund-raising Projects”
3.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/